Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma

This publication has 31 references indexed in Scilit:

• Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma
  Annals of Hematology, 2020
• Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers
  American Journal of Hematology, 2018
• Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
  International Journal of Hematology, 2018
• A Review of Autologous Stem Cell Transplantation in Lymphoma
  Current Hematologic Malignancy Reports, 2017
• BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
  Annals of Hematology, 2016
• Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
  Cancer Chemotherapy and Pharmacology, 2015
• Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation
  Transplantation and Cellular Therapy, 2013
• Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies
  Transplantation and Cellular Therapy, 2011
• BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity
  Annals of Hematology, 2007
• Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
  Transplantation and Cellular Therapy, 2004